Karriereverlauf von Lisa Guttman
Ehemalige bekannte Positionen von Lisa Guttman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Technik-/Wissenschafts-/F&E-Leiter | - | 30.03.2011 |
AMGEN INC. | Corporate Officer/Principal | 01.01.2000 | 01.10.2007 |
ELI LILLY AND COMPANY | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1990 | 01.12.2000 |
Ausbildung von Lisa Guttman
McMaster University | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 4 |
Kanada | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AMGEN INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Private Unternehmen | 1 |
---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
- Börse
- Insiders
- Lisa Guttman
- Erfahrung